Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion

Gastrointestinal Cancer

Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion

Ann Oncol.

O'Reilly EM, Hechtman JF

doi: 10.1093/annonc/mdz385.

Lymphoma

CD19-Directed CAR T Cells Treatment in a Patient With Refractory DLBCL and CNS Involvement

healthbook TIMS Oncology Hematology

Ring A, Müller A

doi: 10.36000/hbT.OH.2019.01.005

Endocrine and Neuroendocrine Tumors (NET)Skin Cancer

Long-Term Sustained Disease Control With Immunotherapy in Chemotherapy-Refractory Merkel Cell Carcinoma

healthbook TIMES Oncology Hematology

Zihlera D, Vollmera K, Cozzio A

doi: 10.36000/hbT.OH.2019.01.003

Lung, Respiratory and Thoracic CancerFurther Publications

Response to Osimertinib in a Patient With Non-Small Cell Lung Cancer and Two Uncommon EGFR mutations

healthbook TIMES Oncology Hematology

Astaras C, Bettini A, Betticher D.C

doi: 10.36000/hbT.OH.2020.03.01

Head and Neck Cancer

Mixed response and mechanisms of resistance to larotrectinib in metastatic carcinoma ex pleomorphic adenoma of the parotid harboring an NTRK2 fusion: A case report

Medicine (Baltimore).

Pircher M, Briner HR, Bonomo M, Horcic M, Petrausch U, Helbling D, Winder T

doi: 10.1097/MD.0000000000024463.

Gastrointestinal Cancer

Multidisciplinary Approach to a Patient with Acinar Cell Carcinoma, a Rare Pancreatic Malignancy

healthbook Times Oncology Hematology

Palmarocchi MC, Merlo E, Cefali M, De Dosso S

doi: 10.36000/hbT.OH.2021.07.029

Gynecologic Cancer

Exceptional Response to Olaparib in a Patient With Recurrent Ovarian Cancer and an Entire BRCA1 Germline Gene Deletion

J Natl Compr Canc Netw.

Randall M, Burgess K, Buckingham L, Usha L

doi: 10.6004/jnccn.2019.7378.

Leukemia

Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy

J Clin Pharm Ther.

Lun Y, Yang JJ, Wu Y

doi: 10.1111/jcpt.12577.